{'fraction_non_alphanumeric': 0.017009847806624886, 'fraction_numerical': 0.0035810205908683975, 'mean_word_length': 5.31638418079096, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[New approaches to the drug prophylaxis of mammary tumor: evaluation of the prophylactic effect of lovastatin and captopril in rats with experimental mammary gland tumors].

Effects of the GABA-CoA reductase inhibitor lovastatin and the ACE inhibitor captopril on the induction and growth of mammary gland tumors induced by N-methyl-N-nitrosourea in Wistar rats have been studied. It is established that lovastatin administered in a doze of 80 mg/kg two times a week exhibits anticarcinogenic activity, which is manifested by a significant decrease in the incidence of neoplasms and an increase in the survival lifetime in the experimental animals. Captopril administered in a doze of 50 mg/kg two times a week significantly decreased the tumor growth rate. The chemopreventive activity of these drugs can be due to their possible regulatory influence on the processes of cell proliferation, differentiation, neoangiogenesis, and apoptosis. The results of this investigation show good prospects for the further investigation of lovastatin and captopril as chemotherapeutic agents for the prophylaxis of mammary tumor.